HOYA Surgical Optics (HSO) has officially launched its new global research and development (R&D) facility in Singapore to develop new breakthrough technologies in intraocular lens (IOL), a lens that is implanted as part of the treatment for cataract.
The new centre is supported by the Singapore Economic Development Board (EDB), and will serve as a Centre of Excellence fighting the growing burden of cataract. With eye disease highlighted as an area of focus within the neurological and sense disorders pillar under the Research, Innovation and Enterprise (RIE) 2020 plan, the establishment of HOYA’s global research facility will help to grow Singapore’s capabilities in this niche area.
John Goltermann Lassen, Chief Executive Officer, HSO, said, “The opening of the HOYA Surgical Optics new global research and development (R&D) facility is a testament to our commitment to further the research and development of innovative products as HOYA continues to set new standards within the industry. The new centre in Singapore will also provide opportunities for collaborations with hospitals, universities and surgeons based in Singapore to uncover new solutions that will deliver better health outcomes for patients here.”
The move makes HOYA the first IOL company in the world to establish worldwide integrated operations in Singapore – with their global headquarters, manufacturing plant and new R&D centre all based in Singapore. It is the second HSO R&D facility in addition to its existing centre in Japan.
Mr Chng Kai Fong, Managing Director, EDB, said, “We are pleased that HOYA Surgical Optics is expanding and deepening their presence in Singapore. The launch of the R&D centre will advance Singapore’s capabilities in intraocular lens technologies, and further strengthen our position as a leading ophthalmology hub. HOYA’s integrated operations here is testament to Singapore’s attractiveness as a base to anchor world-class R&D activities and talent, while building strong competencies in product and process development.”